Compare COUR & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COUR | GERN |
|---|---|---|
| Founded | 2012 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 900.1M |
| IPO Year | 2021 | 1996 |
| Metric | COUR | GERN |
|---|---|---|
| Price | $6.08 | $1.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $12.17 | $3.00 |
| AVG Volume (30 Days) | 3.8M | ★ 11.1M |
| Earning Date | 02-05-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $739,774,000.00 | $183,403,000.00 |
| Revenue This Year | $10.46 | $147.42 |
| Revenue Next Year | $6.16 | $36.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 8.09 | ★ 522.13 |
| 52 Week Low | $5.76 | $1.04 |
| 52 Week High | $13.56 | $3.09 |
| Indicator | COUR | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 25.02 | 50.56 |
| Support Level | $5.98 | $1.29 |
| Resistance Level | $6.37 | $1.40 |
| Average True Range (ATR) | 0.26 | 0.08 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 7.26 | 38.64 |
Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through three reporting segments: Consumer, Enterprise, and Degrees. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.